Drug toxicity is a leading cause of failure in development. Early toxicity identification can change that. At Cyprotex, we use advanced in vitro models to identify safety risks early— ensuring the safest compounds reach the clinic. Learn more about our services here:

A deep understanding of ADME is essential for successful drug discovery and development. Now updated with the latest ICH M12 guidelines, the 6th edition of Cyprotex’s ADME Guide is here for you to explore more. Join thousands of scientists who rely on this must-have resource for

Download your free copy today!

Drug-drug interactions (DDIs) are a major concern in drug development, and staying compliant with evolving regulatory guidelines is more critical than ever. 4th edition of Cyprotex’s DDI Guide breaks down the impact of the latest ICH M12 guidelines on your DDI studies — helping

Meet the Evotec team at #SLAS2025 Dirk Winkler, SVP #HitIdentification, will be presenting on #AI #ML integration and its value in accelerating #DrugDiscovery. Schedule a meeting with Dirk at booth #850 by contacting info@evotec.com.

Meet our team at booth #805 and learn about our research at #SLAS2025. Mélanie Carquin PhD, Team Leader in Evotec’s HTP Biology & Screening group, will be presenting research on RNA #SplicingModulators and their role in drugging ‘undruggable’ targets.

Just - Evotec Biologics is using #AI and #ML to revolutionize #biopharma discovery with a Humanoid #Antibody Library. Our latest publication shows how we validated it by isolating antibodies against SARS-CoV-2. Learn more here-.

Wishing you a joyful holiday season filled with warmth, happiness, and bright new beginnings. From all of us at Evotec, happy holidays and a wonderful new year! 🎄✨

Improve your success in hit identification!.Watch on-demand our Quality Hits at Lightning Speed webinar series Contact us to find out how Evotec can accelerate your project: info@evotec.com . #HitIdentification #HighThroughputScreening #DrugDiscovery

Confidently assess the skin sensitization potential of your test articles with Cyprotex’s OECD-compliant in vitro services. Our comprehensive suite of assays includes: KeratinoSens™, U-SENS™, and DPRA. Contact us to discuss your project: enquiries@cyprotex.com

Read our blog article and learn more about Evotec's end-to-end capabilities for the synthesis, purification, isolation, and quality control of complex modified Oligonucleotides, such as ASOs and siRNAs. #Oligonucleotides #OligonucleotideDrugDiscovery

Missed our joint webinar with Promega, Enabling High-Throughput Screening and Characterization of Targeted Protein Degraders with HiBiT Technology? Watch it now on-demand!. . #HighThroughputScreening #TargetedProteinDegraders

In 2022, Evotec committed to the SBTi Net Zero strategy and we’re making significant progress. With Armstrong International’s innovative heat pump tech, we’ve optimized energy use and cut emissions at our Verona site. Learn more in our latest blog post!

Evotec SE announced that its #DrugDiscovery accelerator with Novo Nordisk, LAB eN², has selected its first three projects to move forward in the program. To learn more, read the full press release here-. #TogetherForMedicinesThaMatter

How to turn a poorly soluble drug into a high performing formulation in just six weeks with scarce API availability? Now on-demand - our case study webinar on ID11916 presented by our #EarlyFormulation expert Fabrizio Fina. #API #Solubility

Now available on-demand - Episode 3 of Evotec's Oligonucleotide Webinar Series exploring innovative tissue engineering and regenerative medicine approaches using miRNAs to treat skeletal injuries. #Oligonucleotides #RegenerativeMedicine #miRNA

Last chance to register and be part of this groundbreaking webinar! . High-Sensitivity Proteomics: The Next Frontier for Spatial and Single-Cell #Biology. Register now and advance your research with high-sensitivity proteomics: #Biologics #Proteomics

Join us on December 10 for the 4th episode of our webinar series on oligo therapies! Dr. Marie Wikström Lindholm, CSO at Silence Therapeutics, will present on: Therapeutic siRNAs: Considerations for “Picking the Best One”. To register: #Oligonucleotides

Read our new article, published in Nature's Biopharma Dealmakers, to learn how we combine therapeutic area expertise with an arsenal of technologies to develop innovative #CellTherapies for a range of disease areas. #iPSC #Immunology #Inflammation

Our T-Cell Immunogenicity Risk Panel delivers critical data on the human immune response triggered by your biotherapeutic. By measuring IL-2 and IFN-γ release from PBMCs, we enable you to identify T-cell mediated immunogenic risks with better precision. #cyprotex #immunotox